Journal: Neuro-Oncology Advances

Article Title: Prediagnostic biomarkers for early detection of glioma—using case–control studies from cohorts as study approach

doi: 10.1093/noajnl/vdac036

Figure Lengend Snippet: Summary of included studies

Article Snippet: 2018 , Brenner et al. , USA , Nested case–control study , 457 cases and 457 matched controls , Median: 15 y, interquartile range: 9–21 y , 14 cytokines , Four sensitive custom V-PLEX Meso Scale Discovery kits (MSD) and 1 standard MSD kits , IL-15 and IL-16 were inversely associated with glioma risks..

Techniques: Biomarker Discovery, Genome Wide, Amplification, Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Ab Array, Multiplex Assay, Concentration Assay, Luminex

Journal: Biomarker Insights

Article Title: Cytokine Profiling in Plasma from Patients with Brain Tumors Versus Healthy Individuals using 2 Different Multiplex Immunoassay Platforms

doi: 10.1177/11772719211006666

Figure Lengend Snippet: Dynamic ranges of the Luminex bead-based fluorescence (LMX) and Meso Scale Discovery electrochemiluminescence (MSD) multiplex cytokine immunoassay kits. Ranges of quantification were determined on standard calibration curves. With 3 exceptions (ie, IFN-γ, IL-8, and IL-21), the low-end of the remaining 16/19 shared analytes’ dynamic ranges was lower with the MSD platform compared to the LMX assay. Conversely, and with 2 exceptions (ie, IL-17A and IL-21), the high-end of the dynamic range was greater with the LMX assay versus the MSD assay. In 2 instances (IL-4 and IL-10), the differences in both upper and lower quantification levels differed by at least an order of magnitude between the 2 assays.

Article Snippet: The second platform was the electrochemiluminescence-based Meso Scale Discovery solid-matrix assay (MSD V-Plex ® kits; Meso Scale Discovery, LLC, Rockville, MD).

Techniques: Luminex, Fluorescence, Electrochemiluminescence, Multiplex Assay

Journal: Biomarker Insights

Article Title: Cytokine Profiling in Plasma from Patients with Brain Tumors Versus Healthy Individuals using 2 Different Multiplex Immunoassay Platforms

doi: 10.1177/11772719211006666

Figure Lengend Snippet: Proportion of donor plasma samples inside the assay quantification range for the Luminex (LMX) and Meso Scale Discovery (MSD) multiplex cytokine immunoassay kits. With the LMX system, all of the 19 shared cytokines were quantifiable in 100% of samples tested. Although the MSD assay had a LLoQ below that of the LMX assay for 17/19 (89) common analytes in earlier standard curve performance evaluations, this sensitivity did not directly translate to evaluating cytokines in human plasma samples. The MSD platform detected and quantified 7 of 19 analytes (37%) in 100% of plasma samples. The MSD assay detection/quantification rate for MIP-1α, IL-12p70, IL-1β, IL-17A, and IFN-γ in samples was 96%, 90%, 86%, 76%, and 75%, respectively. The MSD detection rate was <75% in the remaining 7 of 19 (37%) analytes, including a 0% detection rate for IL-21 and a 8% detection rate for IL-23. Asterisks indicate significant differences for 11/19 analytes between MSD and LMX by Fisher Exact test, with “*” indicating P < .05, “**” indicating P < .01, and “***” indicating P < .001. No asterisk indicates mathematically similar detection frequencies between platforms for those cytokines.

Article Snippet: The second platform was the electrochemiluminescence-based Meso Scale Discovery solid-matrix assay (MSD V-Plex ® kits; Meso Scale Discovery, LLC, Rockville, MD).

Techniques: Luminex, Multiplex Assay

Journal: Biomarker Insights

Article Title: Cytokine Profiling in Plasma from Patients with Brain Tumors Versus Healthy Individuals using 2 Different Multiplex Immunoassay Platforms

doi: 10.1177/11772719211006666

Figure Lengend Snippet: Correlation analysis of concentrations of the 19 cytokines measured in 27 human plasma samples from patients with glioblastoma by the Luminex (LMX) and Meso Scale Discovery (MSD) multiplex assays. Log 2 values of MSD/LMX concentration ratios are shown on the y -axis, and estimate systematic measurement differences between methods when the mean value deviates from zero. A negative shift of the blue mean indicates that the MSD assay classifies the analyte at concentrations lower than LMX, and vice versa. The red ±1.96 SD lines represent 95% limits of agreement, and when SDs are large or n-values are low, then interpretation can be ambiguous. For 17 of 19 shared analytes, the mean concentration ratio was shifted to a positive value, indicating that LMX classified the target cytokine in identical plasma samples at a higher concentration than MSD. The sole exception was with MIP-1β, where MSD characterized samples as containing markedly higher concentrations of cytokine than LMX. Analyte-concentration-dependent effects were suggested by the slope of the mean line, and were notable for IL-7 and MIP-1β. The only cytokine similarly characterized by both assays was IL-8.

Article Snippet: The second platform was the electrochemiluminescence-based Meso Scale Discovery solid-matrix assay (MSD V-Plex ® kits; Meso Scale Discovery, LLC, Rockville, MD).

Techniques: Luminex, Multiplex Assay, Concentration Assay